"Dear Shareholders,
2021 was a particularly important year in the history of our Group, not only for the outstanding results delivered in terms of revenues, profitability, cash flow generation and profit, but also for the acquisition of Luminex Corporation -the largest ever made by DiaSorin- completed in July.

Against this challenging backdrop marked by the COVID-19 pandemic, our Company remained true to the desire to expand our technology and commercial offering, both through the ongoing commitment of our researchers, and thanks to partnerships with innovative in vitro diagnostics companies.

The strengthening of DiaSorin's role as a diagnostic specialist and a global player was a significant input towards the Luminex acquisition, a leading company in the fields of multiplexing molecular diagnostics and Life Science. This event marked the beginning of DiaSorin’s new business cycle that was presented in December during the Investor Day 2021 along with several projects, which the Management is very proud of, and that will drive the Group towards an even stronger growth in the next 4 years.

The role of "Specialist" was also confirmed by the development and launch of nearly 30 immunodiagnostic and molecular diagnostic products over the last 3 years. In 2021, in particular, we launched several products with top-quality partners in terms of innovation and technology. Among these, the test for the early diagnosis of Lyme disease, developed in partnership with Qiagen, the launch of the LIAISON® IQ platform, with the first two tests for detection of specific antibodies against SARS-CoV-2 and diagnosis of COVID-19 infection and the launch of the MeMed BV® test for differentiation between bacterial and viral infections, which are the result of the innovative approach to diagnostics of the Israeli MeMed company.

Aware of the crucial role that diagnostics and research play in a complex global scenario where the pandemic has not yet been defeated, DiaSorin enters 2022 with significant and increasingly ambitious projects in the diagnostic and Licensed Technologies sectors. This new business area resulting from the Luminex acquisition supports DiaSorin’s access to scientific research and expands engagement with diagnostic players or international pharma companies, providing further growth opportunities on a global scale.

In a year so full of events, it is my duty to thank, once again, the Group’s management who tackled the challenges and opportunities of the past year with an entrepreneurial spirit, along with the over 3,300 people who, through their extraordinary work, make DiaSorin a global and innovative excellence.

Last but not least, Dear Shareholders, let me express my gratitude to you for your trust that inspires us to always do better, consolidating the important role the DiaSorin Group plays worldwide in the healthcare sector and touching, every year, millions of lives with its specialty products and solutions."

The Chairman
Gustavo Denegri

DISCOVER MORE
CLOSE
IMMUNODIAGNOSTICS
MOLECULAR DIAGNOSTICS
LICENSED TECHNOLOGIES
IMMUNODIAGNOSTICS
LIAISON® XL
X Close
In 2021, the LIAISON® XL strengthened its international presence by leveraging its flexibility, which enables quick and reliable results, and the wide range of both specialty and routine diagnostic tests. The LIAISON® XL platform provides highly-automated solutions, both in stand-alone configuration and through the connection with the main market players’ systems (XL LAS).
LIAISON® XS
X Close
In 2021, DiaSorin resumed the LIAISON® XS rollout, by leveraging the features that make it the most suitable platform for laboratories with low and medium specialty test volumes. LIAISON® XS is also the best solution for diagnostic facilities distributed across the territory: routine testing is performed in a centralized reference "hub", which offers high-throughput processing in a very short time, while specialty testing, for which greater proximity to the patient is deemed necessary, is performed in smaller decentralized diagnostic facilities.
MOLECULAR DIAGNOSTICS
LIAISON® MDX
X Close
The LIAISON® MDX analyzer features a compact and flexible design and can be used in association with the following consumables:
  • the “Direct Amplification Disc (DAD)” consumable for fast, “on demand” results, also at laboratories with low-volume testing, or during urgent procedures such as, for example, the identification of patients to be isolated in hospitals;
  • the “Universal Disc (UD)” for routine, screening or high-throughput results
ARIES®
X Close
It’s a “Sample-to-answer” platform capable of detecting, along with LIAISON® MDX, a limited number of pathogens for each reagent (single-low plex platform).
The Aries® platform allows laboratories to control every aspect of the sample-to-answer testing process and it allows multiple sample types and up to 12 different IVD assays.
ARIES® cassettes contain all of the reagents needed to run PCR testing on a sample. All the test phases, including extraction and purification do not require external control or equipment. ARIES® cassettes are also color coded and can be stored at room temperature
VERIGENE®
X Close
It’s a multiplex platform capable of identifying a wide range of parameters from a single biological sample.
The VERIGENE® system is scalable, allowing throughput customization to meet the size and testing demands of each laboratory. Panels available on the VERIGENE® platform are designed to target infections in the bloodstream, respiratory tract, and gastrointestinal tract. VERIGENE® tests cartridges are single-use and each test cartridge is designed for multiplex analysis of one patient sample.
LICENSED TECHNOLOGIES
xMAP INTELLIFLEX®
X Close
In the first half of 2021, Luminex launched the xMAP INTELLIFLEX®, the next generation platform developed for the scientific research market.
The xMAP INTELLIFLEX® platform features a dual reporter functionality thanks to which the user can acquire data on two parameters per target protein or nucleic acid, saving time and generating higher volumes of data from a smaller number of samples..

Development of new products

IMMUNODIAGNOSTICS
MOLECULAR DIAGNOSTICS
LICENSED TECHNOLOGIES

LIAISON® SARS-CoV-2 TrimericS IgG

A new quantitative serology test for determination of IgG antibodies against SARS-CoV-2 in patients that were either subject to natural infections or vaccinated against COVID-19. It’s available in countries accepting the CE Mark and approved in the U.S. through Emergency Use Authorization.

LIAISON® Lyme IgM AND LIAISON® Lyme IgG

Test for the identification of IgG and IgM antibodies against Borrelia burgdorferi, a pathogen responsible for Lyme Borreliosis (or Lyme disease), available both in countries accepting the CE Mark and in the U.S.

LIAISON® SARS-CoV-2 Ag

Antigen test to identify SARS-CoV-2 in symptomatic patients, available in countries accepting the CE Mark and approved in the U.S. through Emergency Use Authorization.

LIAISON® LymeDetect®

Test developed in partnership with QIAGEN for the early diagnosis of Lyme Borreliosis infection, available on LIAISON® platforms in countries accepting the CE mark.

LIAISON® IQ and LIAISON® Quick Detect COVID TrimericS Ab

Point-of-Care immunodiagnostic platform, developed in collaboration with Lumos Diagnostics, and its first test for the detection of specific IgG antibodies against SARS-CoV-2 from a capillary blood sample using lateral flow technology. Both products are available in countries accepting CE mark.

LIAISON® Murex AntiHEV IgG & IgM

Test for the diagnosis of Hepatitis E on LIAISON® platforms, available in all countries accepting CE mark. It is the first CLIA fully automated high-throughput solution launched for the diagnosis of Hepatitis E (HEV).

LIAISON® MeMed BV®

Test to differentiate accurately between bacterial and viral infections.This new test was developed in collaboration with the Israeli company MeMed and launched in countries accepting the CE mark.

Simplexa SARS-CoV-2 Variants Direct (Research Use Only)

Research Use Only test for the detection of mutations of the SARS-CoV-2 virus, designed to simplify the monitoring of the spread of the variants of concern.

Simplexa COVID-19 & Flu A/B

Test that identifies and distinguishes a broad spectrum of mutations of both the SARS-CoV-2 virus and flu A and B.

xMAP INTELLIFLEX®

Compact, flow-based multiplex platform that combines the performance of xMAP® technology with advanced features to improve performance, support innovation and test development, and simplify the user experience. It is the only multiplex platform that combines low-plex and high-plex capabilities, speed of execution with reliable results and the ability to simultaneously acquire data for two parameters per analyte.

Group key data
3,358
TOTAL EMPLOYEES
24
COUNTRIES WITH DIRECT PRESENCE AND DISTRIBUTORS IN 93 COUNTRIES
> 400
PEOPLE DEDICATED TO R&D
9
R&D CENTRES AROUND THE WORLD

Download
2021 Report

DOWNLOAD